. 2020 Jul 3;24(2):87–95. doi: 10.5114/wo.2020.97520

Table 2.

Association between clinicopathological findings and ITM2A in included triple-negative breast cancer patients

Characteristics		All (n = 120)	ITM2A		p-value	ITM2A (%)		p-value
		All (n = 120)	Low (n = 64)	High (n = 56)		Mean ±SD	Median (range)
		n (%)	n (%)	n (%)		Mean ±SD	Median (range)
Age (years)
	Mean ±SD	56.23 ±10.99	61.28 ±10.77	50.46 ±8.14	< 0.001^a
	Median (range)	56 (39–87)	60 (40–87)	49 (39–67)	< 0.001^a
	≤ 50 years	46 (38.3)	10 (15.6)	18 (64.3)	0.009^b	67.82 ±24.57	80 (20–90)	< 0.001^a
	> 50 years	74 (61.7)	54 (84.4)	10 (35.7)	0.009^b	22.70 ±26.77	15 (0–90)	< 0.001^a
Size (cm)
	Mean ±SD	6.33 ±3.59	8.50 ±2.70	3.85 ±2.82	< 0.001^a
	Median (range)	7 (1–13)	9 (3–13)	3 (1–9)	< 0.001^a
	< 5 cm	48 (40)	10 (15.6)	19 (67.9)	0.006^b	68.75 ±24.46	80 (20–90)	< 0.001^a
	≥ 5 cm	72 (60)	54 (84.4)	9 (32.1)	0.006^b	20.83 ±24.58	15 (0–80)	< 0.001^a
Grade
	Grade I	20 (16.7)	6 (9.4)	7 (25)	0.004^b	59 ±25.47	70 (20–80)	< 0.001^a
	Grade II	30 (25)	4 (6.3)	13 (46.4)		76 ±21.23	80 (25–90)
	Grade III	70 (58.3)	54 (84.4)	8 (28.6)		19.14 ±22.72	15 (0–80)
Lymph node
	Negative	38 (31.7)	0 (0)	19 (67.9)	0.002^b	78.42 ±7.64	80 (60–90)	< 0.001^a
	Positive	82 (68.3)	64 (100)	9 (32.1)	0.002^b	22.19 ±25.43	20 (0–90)	< 0.001^a
T
	T1	26 (21.7)	0 (0)	13 (46.4)	< 0.001^b	82.30 ±4.38	80 (80–90)	< 0.001^a
	T2	22 (18.3)	10 (15.6)	6 (21.4)		52.72 ±28.84	60 (20–90)
	T3	44 (36.7)	26 (40.6)	9 (32.1)		29.95 ±27.21	23 (0–80)
	T4	28 (23.3)	28 (43.8)	0 (0)		6.50 ±8.33	0 (0–24)
N
	N0	38 (31.7)	0 (0)	19 (67.9)	0.005^b	78.42 ±7.64	80 (60–90)	< 0.001^a
	N1	14 (11.7)	0 (0)	7 (25)		70 ±21.60	80 (40–90)
	N2	42 (35)	40 (62.5)	1 (3.6)		16.14 ±10.18	20 (0–25)
	N3	26 (21.7)	24 (37.5)	1 (3.6)		6.23 ±8.81	0 (0–22)
Stage
	Stage I	18 (15)	0 (0)	9 (32.1)	0.007^b	81.11 ±3.33	80 (80–90)	< 0.001^a
	Stage II	28 (23.3)	0 (0)	14 (50)		78.57 ±9.49	80 (60–90)
	Stage III	42 (35)	32 (50)	5 (17.9)		21.85 ±16.49	24 (0–70)
	Stage IV	32 (26.7)	32 (50)	0 (0)		6.93 ±7.46	5 (0–20)

Mann-Whitney U test